Preliminary safety and efficacy results from phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with anti-PD-1 mAb CS1003 in patients with advanced solid tumors

被引：1
|
作者：
Bishnoi, S. [1 ]
Cosman, R. [2 ]
Moore, M. [3 ]
Eek, R. [4 ]
Mant, A. [5 ]
Zielinski, R. [6 ]
Chan, L. S. [7 ]
Ma, Y. [8 ]
Zhang, Q. [9 ]
Yau, T. [10 ]
Aghmesheh, M. [11 ]
Tse, A. N. [9 ]
机构：
[1] Ashford Canc Ctr Res, Dept Med Oncol, Adelaide, SA, Australia
[2] St Vincents Hosp, Dept Med Oncol, Sydney, NSW, Australia
[3] Alfred Hosp, Dept Med Oncol, Melbourne, Vic, Australia
[4] Border Med Oncol, Dept Med Oncol, Albury, NSW, Australia
[5] Box Hill Hosp, Dept Oncol, Melbourne, Vic, Australia
[6] Orange Hlth Serv, Oncol Unit, Orange, NSW, Australia
[7] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, Hong Kong, Peoples R China
[8] CStone Pharmaceut Su Zhou Co Ltd, Clin Dept, Suzhou, Peoples R China
[9] CStone Pharmaceut Suzhou Co Ltd, Translat Med & Early Dev, Suzhou, Peoples R China
[10] Queen Mary Hosp, Dept Med, Hong Kong, Peoples R China
[11] Southern Mediacal Day Care Ctr, Dept Med Oncol, Wollongong, NSW, Australia
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1365
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
981P
引用
收藏
页码：S840 / S840
页数：1
相关论文
共 50 条
  • [1] Preliminary safety and efficacy results from phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with anti-PD-1 mAb CS1003 in patients with advanced solid tumors
    Bishnoi, S.
    Yau, T.
    Cosman, R.
    Aghmesheh, M.
    Moore, M.
    Chan, S. L.
    Mant, A.
    Eek, R.
    Zielinski, R.
    Li, P.
    Wang, H.
    Ma, Y.
    Tse, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S1437 - S1438
  • [2] A first-in-human phase I dose escalation of YH001, an anti-CTLA-4 monoclonal antibody (mAb), in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors
    Ganju, Vinod
    Cooper, Adam
    Gao, Bo
    Wilkinson, Kate
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] A first-in-human phase I dose escalation of YH001, an anti-CTLA-4 monoclonal antibody (mAb) in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors.
    Ganju, Vinod
    Cooper, Adam
    Gao, Bo
    Wilkinson, Kate
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] Dual CTLA-4 and PD-1 checkpoint blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors: A first-in-human, dose-escalation, and dose-expansion study
    Bishnoi, Sarwan
    Kotasek, Dusan
    Aghmesheh, Morteza
    Yau, Thomas
    Cosman, Rasha
    Prawira, Amy
    Moore, Maggie
    Chan, Stephen L.
    Mant, Andrew
    Eek, Richard
    Zielinski, Robert
    Su, Rila
    Pan, Zhaoxuan
    Ma, Yiding
    Li, Fei
    Li, Peiqi
    Tse, Archie N.
    CANCER, 2024, 130 (11) : 1991 - 2002
  • [5] A phase Ia/Ib trial of the anti-PD-L1 human monoclonal antibody (mAb), CS1001, in patients (pts) with advanced solid tumors or lymphomas.
    Shen, Lin
    Cao, Junning
    Li, Jin
    Pan, Hongming
    Xu, Nong
    Zhang, Yan
    Wang, Jingru
    Wang, Yin
    Dai, Hangjun
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] IBI110 (anti-LAG-3 mAb) as a single agent or in combination with sintilimab (anti-PD-1 mAb) in patients with advanced solid tumors: Updated results from the phase Ia/Ib dose-escalation study
    Xu, Nong
    Mao, Chenyu
    Qian, Jiong
    Zheng, Yulong
    Jiang, Haiping
    Gao, Yuan
    Xiao, Cheng
    Xiong, Anwen
    Li, Wei
    He, Yayi
    Ren, Shengxiang
    Wang, Lei
    Yu, Jia
    Zhu, Jun
    Liu, Ying
    Zhou, Caicun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [7] Preliminary safety, pharmacokinetics (PK) and efficacy results from a phase I study of CS1001, an anti-programmed death ligand-1 (PD-L1) monoclonal antibody (mAb) in patients (pts) with advanced tumors
    Shen, L.
    Cao, J.
    Gong, J.
    Ji, D.
    Qin, Z.
    Dai, H.
    Wu, K.
    Xu, J.
    Yang, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [8] AGEN1181, AN FC-ENHANCED ANTI-CTLA-4 ANTIBODY, ALONE AND IN COMBINATION WITH BALSTILIMAB (ANTI-PD-1) IN PATIENTS WITH ADVANCED SOLID TUMORS: INITIAL PHASE I RESULTS
    El-Khoueiry, Anthony
    Bullock, Andrea
    Tsimberidou, Apostolia
    Mahadevan, Daruka
    Wilky, Breelyn
    Twardowski, Przemyslaw
    Bockorny, Bruno
    Moser, Justin
    Feliu, Waldo Ortuzar
    Grossman, Joseph
    Rosenthal, Katherine
    O'Day, Steven
    Gordon, Michael
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A509 - A509
  • [9] Efficacy and safety of sintilimab (anti-PD-1 mAb) for advanced cervical cancer: Results from a Phase II trial
    Gao, Qinglei
    Wang, Jing
    Xu, Qin
    Tang, Ying
    Zhang, Jieqing
    Chang, Baoping
    Xia, Bairong
    Duan, Wei
    Wang, Danbo
    Zhu, Lijing
    An, Ruifang
    Zhang, Guonan
    Tang, Yaling
    Huang, Jianli
    Zhang, Xiang
    Qiu, Hui
    Ji, Wenting
    Li, Li
    Zhu, Jianqing
    Ma, Ding
    CANCER RESEARCH, 2023, 83 (08)
  • [10] Initial results of a phase 1b/2 study of ADG126 (a masked anti-CTLA-4 SAFEbody ®) in combination with pembrolizumab (an anti-PD-1 antibody) in patients with advanced/metastatic solid tumors
    Li, Daneng
    Sharma, Sunil
    She, Kristine
    Li, Wenda
    Li, Ai
    Zheng, Songmao
    Liu, Guizhong
    Ndukwo, Ogon
    Hu-Lowe, Dana
    Chisamore, Michael
    Luo, Peter
    Zha, Jiping
    Patel, Manish R.
    CANCER RESEARCH, 2023, 83 (08)
12345